NK - 1 Antagonist Drug Interactions
from OncoPharm Hosted by John Bossaer
Drug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant. A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on February 6, 2020.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.